Article info

Download PDFPDF

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

Authors

  • Lauren Yokomizo Stanford University School of Medicine, Stanford University, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Berkeley Limketkai Stanford University School of Medicine, Stanford University, Palo Alto, California, USA Department of Medicine, Division of Gastroenterology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • K T Park Stanford University School of Medicine, Stanford University, Palo Alto, California, USA Department of Pediatrics, Division of Gastroenterology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr KT Park; ktpark{at}stanford.edu
View Full Text

Citation

Yokomizo L, Limketkai B, Park KT
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

Publication history

  • Received March 22, 2016
  • Revised April 11, 2016
  • Accepted April 13, 2016
  • First published May 1, 2016.
Online issue publication 
May 01, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.